Evidence map›Paper›PMID 36831076›Full record

ArticleBiomedicines2023

Colorectal Cancer (CRC): Investigating the Expression of the Suppressor of Fused (

Tahseen Bilal Rather, Ishrat Parveiz, Gulzar A Bhat, Gowhar Rashid, Kulsum Akhtar, Rizwanul Haque, Mohammad Shamsul Ola, Mehboob Ali, Rauf A Wani, Ishrat Younas Khan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Red cell distribution width as a prognostic predictor for colorectal cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Tahseen Bilal RatherDepartment of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Ishrat ParveizDepartment of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Gulzar A BhatScientist Multidisciplinary Research Unit, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Gowhar RashidDepartment of Amity Medical School, Amity University Haryana, Haryana 125001, India.
Kulsum AkhtarDepartment of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Rizwanul HaqueDepartment of Biotechnology, SEBES, Central University of South Bihar (Gaya), Bihar 824236, India.
Mohammad Shamsul OlaDepartment of Biochemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-7479-8970
Mehboob AliSenior Scientist Toxicology Invivotek Nexus, a Genesis Biotech Group LLC Company, 17 Black Forest RD, Hamilton, NJ 08690, USA.
Rauf A WaniDepartment of General Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.ORCID 0000-0003-1182-7903
Ishrat Younas KhanDepartment of Pathology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Syed BesinaDepartment of Pathology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Syed MudassarDepartment of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, India.
Sher-i-Kashmir Institute of Medical Sciences · INCentral University of South Bihar · INKing Saud University · SA

Funding

The study was funded by Sher-I- Kashmir Institute of Medical Sciences, Kashmir, India; SIMS/ACAD 877 OF 2019
6 · The paper itself

Abstract

backgroundSuppressor of fused (

aimOur goal was to look at

methodsThe investigation included 98 histopathologically confirmed CRC samples and adjacent normal tissues (controls). A colonoscopy was followed by a targeted biopsy for each suspected colon cancer patient. A CT scan and MRI were also performed on every patient with rectal cancer. Real-time polymerase chain reaction and immunohistochemistry (IHC) were used for assessment. A Beckman Coulter DxH900 was used to examine blood parameters. A Beckman Coulter DxI800 was used to identify pretreatment carcinoma embryonic antigens (CEA) and carbohydrate antigens (CA 19-9) in CRC patients.

resultsThe expression of

conclusionIn CRC,

Indexed as

colorectal cancerimmunohistochemistryKashmirquantitative real-time PCRSuFu

Identifiers

PMID36831076
PMCPMC9953361
OpenAlexW4320485900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.